PureTech Health plc American Depositary Shares - PRTC STOCK NEWS

PureTech Health plc (Nasdaq: PRTC) announced a definitive agreement for its Founded Entity, Gelesis, Inc., to merge with Capstar Special Purpose Acquisition Corp. (NYSE: CPSR). This transaction aims to list the combined company on the NYSE under the symbol 'GLS' and has an implied enterprise value of approximately $1.0 billion. Gelesis expects to secure up to $376 million in gross proceeds, primarily for the commercial launch of its FDA-cleared weight management product, Plenity. This merger showcases PureTech's unique model for creating value through its Founded Entities.

PureTech Health plc (Nasdaq: PRTC) announces a collaboration between its Founded Entity, Vor Biopharma (Nasdaq: VOR), and Janssen Biotech, Inc.. The partnership aims to explore combining Vor's engineered hematopoietic stem cell transplant platform with Janssen's bi-specific antibodies targeting acute myeloid leukemia (AML). Each company retains ownership of its respective technologies. Vor's Chief Scientific Officer expressed enthusiasm about leveraging both technologies to improve cancer treatment while minimizing side effects. This collaboration is a significant step in advancing innovative cancer therapies.

PureTech Health (PRTC) announced that its Founded Entity, Sonde Health, will collaborate with Qualcomm to enhance Sonde's vocal biomarker technology for the Snapdragon 888 and 778G 5G Mobile Platforms. This partnership aims to integrate machine learning-driven vocal biomarker capabilities into mobile and IoT devices, potentially enabling various health monitoring applications on millions of devices. Sonde’s technology can detect conditions like asthma and COVID-19 through voice analysis, paving the way for innovative, native health features directly on devices, ensuring faster and more secure health monitoring.

PureTech Health plc (Nasdaq: PRTC) has announced a clinical trial and supply agreement with BeiGene to evaluate tislelizumab, an anti-PD-1 immune checkpoint inhibitor, in combination with PureTech’s investigational monoclonal antibody LYT-200. This collaboration aims to address difficult-to-treat solid tumors. PureTech will control the LYT-200 program and expects to report topline Phase 1 results in Q4 2021. Tislelizumab is approved in China for multiple solid tumor indications, with ongoing trials aimed at expanding its use.

PureTech Health (Nasdaq: PRTC) announces that Vedanta Biosciences, its Founded Entity, presented additional results from the Phase 1 study of VE202, a 16-strain live biotherapeutic product candidate for inflammatory bowel disease (IBD) at the International Human Microbiome Consortium Congress 2021. The study showed VE202 was safe and well-tolerated with no serious adverse events. Vedanta plans to initiate a Phase 2 trial in ulcerative colitis patients, partially funded by a $25 million investment from Pfizer.

Vedanta Biosciences announced results from a Phase 1 study of VE202, a 16-strain live biotherapeutic product for inflammatory bowel disease (IBD), presented at the International Human Microbiome Consortium Congress 2021. The study showed VE202 was safe, well-tolerated, and led to durable colonization in healthy volunteers. Vedanta plans to advance VE202 to a Phase 2 trial for ulcerative colitis, funded partially by a $25 million investment from Pfizer. IBD affects approximately 3 million people in the U.S., highlighting the need for innovative treatments.

PureTech Health plc (Nasdaq: PRTC) expresses optimism following its Founded Entity, Karuna, announcing results from a Phase 1b trial of KarXT (xanomeline-trospium) in healthy elderly volunteers. The trial demonstrated that KarXT could be administered at therapeutic doses with a favorable safety and tolerability profile. Karuna plans to launch a Phase 2 trial targeting dementia-related psychosis in the first half of 2022. The majority of participants tolerated doses between 150-200 mg. PureTech holds an 8.2% stake in Karuna and is set to receive royalty payments from future net sales.

PureTech Health (Nasdaq: PRTC) has acquired the remaining 22% of shares in Alivio Therapeutics, enhancing its pipeline targeting inflammatory disorders like inflammatory bowel disease (IBD). This acquisition integrates Alivio’s technology into PureTech’s Wholly Owned Pipeline, including LYT-500, an oral treatment for IBD. This strategic move is set to be funded through partnerships and grants, aligning with PureTech's financial plan extending into Q1 2025. The transaction consists of a cash payment and future milestone payments, which are categorized as smaller transactions under listing rules.

The Annual General Meeting of PureTech Health plc (Nasdaq: PRTC) took place on May 27, 2021, with all proposed resolutions passing successfully. Key results include:

• Approval of the Annual Report for 2020: 100% votes in favor.
• Directors’ Remuneration Report: 89.74% approval.
• Directors’ Remuneration Policy: 83.90% approval.
• Election of directors Dr. Raju Kucherlapati and Dame Marjorie Scardino received 98.73% and 98.54% approval, respectively.
• Reappointment of KPMG LLP as Auditors: 99.90% approval.

These results reflect strong shareholder support for the Company's governance and financial reporting.